BUSCARINO, MICHELA
BUSCARINO, MICHELA
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
2011-01-01 Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A†; Trusolino L† (†Co-Senior authors)
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
2016-01-01 Van Emburgh, Beth O; Arena, Sabrina; Siravegna, Giulia; Lazzari, Luca; Crisafulli, Giovanni; Corti, Giorgio; Mussolin, Benedetta; Baldi, Federica; Buscarino, Michela; Bartolini, Alice; Valtorta, Emanuele; Vidal, Joana; Bellosillo, Beatriz; Germano, Giovanni; Pietrantonio, Filippo; Ponzetti, Agostino; Albanell, Joan; Siena, Salvatore; Sartore-Bianchi, Andrea; Di Nicolantonio, Federica; Montagut, Clara; Bardelli, Alberto
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
2014-01-01 S. Misale;S. Arena;S. Lamba;G. Siravegna;A. Lallo;S. Hobor;M. Russo;M. Buscarino;L. Lazzari;A. Sartore-Bianchi;K. Bencardino;A. Amatu;C. Lauricella;E. Valtorta;S. Siena;F. Di Nicolantonio;A. Bardelli
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer
2012-01-01 Misale, S; Yaeger, R; Hobor, S; Scala, E; Janakiraman, M; Liska, D; Valtorta, E; Schiavo, R; Buscarino, M; Siravegna, G; Bencardino, K; Cercek, A; Chen, Ct; Veronese, S; Zanon, C; Sartore-Bianchi, A; Gambacorta, M; Gallicchio, M; Vakiani, E; Boscaro, V; Medico, E; Weiser, M; Siena, S; Di Nicolantonio, F; Solit, D; Bardelli, A.
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
2017-01-01 Oddo, D; Siravegna, G; Gloghini, A; Vernieri, C; Mussolin, B; Morano, F; Crisafulli, G; Berenato, R; Corti, G; Volpi, Cc; Buscarino, M; Niger, M; Dunne, Pd; Rospo, G; Valtorta, E; Bartolini, A; Fucà, G; Lamba, S; Martinetti, A; Di Bartolomeo, M; de Braud, F; Bardelli, A; Pietrantonio, F; Di Nicolantonio, F.
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer
2011-01-01 Molinari F*; Felicioni L*; Buscarino M*; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabisio O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A;† Frattini M† (*Shared first authorship - †Co-Senior authors)
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS
2012-01-01 Giorgia Migliardi; Francesco Sassi; Davide Torti; Francesco Galimi; Eugenia R. Zanella; Michela Buscarino; Dario Ribero; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Mauro Risio; Lorenzo Capussotti; Silvia Marsoni; Federica Di Nicolantonio; Alberto Bardelli; Paolo M. Comoglio; Livio Trusolino*; Andrea Bertotti* (*Co-Senior Authors)
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer
2016-01-01 Oddo, D; Sennott, Em; Barault, L; Valtorta, E; Arena, S; Cassingena, A; Filiciotto, G; Marzolla, G; Elez, E; van Geel RM, ; Bartolini, A; Crisafulli, G; Boscaro, V; Godfrey, Jt; Buscarino, M; Cancelliere, C; Linnebacher, M; Corti, G; Truini, M; Siravegna, G; Grasselli, J; Gallicchio, M; Bernards, R; Schellens, Jh; Tabernero, J; Engelman, Ja; Sartore-Bianchi, A; Bardelli, A; Siena, S; Corcoran, Rb; Di Nicolantonio, F.
The endangered white-clawed crayfish Austropotamobius pallipes (Decapoda, Astacidae) east and west of the Maritime Alps: a result of human translocation?
2011-01-01 Fabrizio Stefani;Serena Zaccara;Giovanni B. Delmastro;Michela Buscarino
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
2015-01-01 Medico, E; Russo, M; Picco, G; Cancelliere, C; Valtorta, E; Corti, G; Buscarino, M; Isella, C; Lamba, S; Martinoglio, B; Veronese, S; Siena, S; Sartore-Bianchi, A; Beccuti, M; Mottolese, M; Linnebacher, M; Cordero, F; Di Nicolantonio, F*; Bardelli, A*; (*co-last and *corresponding authors)
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
2017-01-01 Siravegna, G; Sartore-Bianchi, A; Mussolin, B; Cassingena, A; Amatu, A; Novara, L; Buscarino, M; Corti, G; Crisafulli, G; Bartolini, A; Tosi, F; Erlander, M; Di Nicolantonio, F; Siena, S; Bardelli, A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | 2011 | Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A†; Trusolino L† (†Co-Senior authors) | |
| Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer | 2016 | Van Emburgh, Beth O; Arena, Sabrina; Siravegna, Giulia; Lazzari, Luca; Crisafulli, Giovanni; Corti, Giorgio; Mussolin, Benedetta; Baldi, Federica; Buscarino, Michela; Bartolini, Alice; Valtorta, Emanuele; Vidal, Joana; Bellosillo, Beatriz; Germano, Giovanni; Pietrantonio, Filippo; Ponzetti, Agostino; Albanell, Joan; Siena, Salvatore; Sartore-Bianchi, Andrea; Di Nicolantonio, Federica; Montagut, Clara; Bardelli, Alberto | |
| Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer | 2014 | S. Misale;S. Arena;S. Lamba;G. Siravegna;A. Lallo;S. Hobor;M. Russo;M. Buscarino;L. Lazzari;A. Sartore-Bianchi;K. Bencardino;A. Amatu;C. Lauricella;E. Valtorta;S. Siena;F. Di Nicolantonio;A. Bardelli | |
| Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer | 2012 | Misale, S; Yaeger, R; Hobor, S; Scala, E; Janakiraman, M; Liska, D; Valtorta, E; Schiavo, R; Buscarino, M; Siravegna, G; Bencardino, K; Cercek, A; Chen, Ct; Veronese, S; Zanon, C; Sartore-Bianchi, A; Gambacorta, M; Gallicchio, M; Vakiani, E; Boscaro, V; Medico, E; Weiser, M; Siena, S; Di Nicolantonio, F; Solit, D; Bardelli, A. | |
| Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer | 2017 | Oddo, D; Siravegna, G; Gloghini, A; Vernieri, C; Mussolin, B; Morano, F; Crisafulli, G; Berenato, R; Corti, G; Volpi, Cc; Buscarino, M; Niger, M; Dunne, Pd; Rospo, G; Valtorta, E; Bartolini, A; Fucà, G; Lamba, S; Martinetti, A; Di Bartolomeo, M; de Braud, F; Bardelli, A; Pietrantonio, F; Di Nicolantonio, F. | |
| Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer | 2011 | Molinari F*; Felicioni L*; Buscarino M*; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabisio O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A;† Frattini M† (*Shared first authorship - †Co-Senior authors) | |
| INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS | 2012 | Giorgia Migliardi; Francesco Sassi; Davide Torti; Francesco Galimi; Eugenia R. Zanella; Michela Buscarino; Dario Ribero; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Mauro Risio; Lorenzo Capussotti; Silvia Marsoni; Federica Di Nicolantonio; Alberto Bardelli; Paolo M. Comoglio; Livio Trusolino*; Andrea Bertotti* (*Co-Senior Authors) | |
| Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer | 2016 | Oddo, D; Sennott, Em; Barault, L; Valtorta, E; Arena, S; Cassingena, A; Filiciotto, G; Marzolla, G; Elez, E; van Geel RM, ; Bartolini, A; Crisafulli, G; Boscaro, V; Godfrey, Jt; Buscarino, M; Cancelliere, C; Linnebacher, M; Corti, G; Truini, M; Siravegna, G; Grasselli, J; Gallicchio, M; Bernards, R; Schellens, Jh; Tabernero, J; Engelman, Ja; Sartore-Bianchi, A; Bardelli, A; Siena, S; Corcoran, Rb; Di Nicolantonio, F. | |
| The endangered white-clawed crayfish Austropotamobius pallipes (Decapoda, Astacidae) east and west of the Maritime Alps: a result of human translocation? | 2011 | Fabrizio Stefani;Serena Zaccara;Giovanni B. Delmastro;Michela Buscarino | |
| The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets | 2015 | Medico, E; Russo, M; Picco, G; Cancelliere, C; Valtorta, E; Corti, G; Buscarino, M; Isella, C; Lamba, S; Martinoglio, B; Veronese, S; Siena, S; Sartore-Bianchi, A; Beccuti, M; Mottolese, M; Linnebacher, M; Cordero, F; Di Nicolantonio, F*; Bardelli, A*; (*co-last and *corresponding authors) | |
| Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor | 2017 | Siravegna, G; Sartore-Bianchi, A; Mussolin, B; Cassingena, A; Amatu, A; Novara, L; Buscarino, M; Corti, G; Crisafulli, G; Bartolini, A; Tosi, F; Erlander, M; Di Nicolantonio, F; Siena, S; Bardelli, A |